Stock 6099 ELAN CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

Financials Elan Corporation

Equities

6099

JP3167680002

Healthcare Facilities & Services

Market Closed - Japan Exchange
Other stock markets
 02:00:00 2024-05-02 am EDT 		5-day change 1st Jan Change
903 JPY -0.22% Intraday chart for Elan Corporation +0.78% -19.09%
Feb. 14 Elan Corporation Provides Consolidated Earnings Guidance for the Six Month Ending June 30, 2024 and Full Year Ending December 31, 2024 CI
Feb. 14 Elan Corporation Provides Dividend Guidance for the Full Year Ending December 31, 2024 CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 48,782 90,838 67,110 56,713 67,475 54,596 - -
Enterprise Value (EV) 1 45,310 86,341 61,478 50,677 61,987 54,596 54,596 54,596
P/E ratio 49.3 x 62.8 x 35.2 x 27.2 x 26.8 x 19.2 x 16.1 x 12.8 x
Yield 0.56% 0.47% 0.81% 1.17% 1.16% 1.55% 1.88% 2.21%
Capitalization / Revenue 2.27 x 3.49 x 2.12 x 1.56 x 1.63 x 1.11 x 0.94 x 0.83 x
EV / Revenue 2.27 x 3.49 x 2.12 x 1.56 x 1.63 x 1.11 x 0.94 x 0.83 x
EV / EBITDA 30.4 x 41.6 x 23.3 x 16.1 x - 12.4 x 10.5 x 8.48 x
EV / FCF 68,131,687 x 48,011,668 x - 44,203,140 x 38,645,320 x - - -
FCF Yield 0% 0% - 0% 0% - - -
Price to Book 9.72 x 14.7 x 8.97 x 6.31 x 6.24 x 4.26 x 3.59 x 3 x
Nbr of stocks (in thousands) 60,599 60,599 60,459 60,461 60,461 60,461 - -
Reference price 2 805.0 1,499 1,110 938.0 1,116 903.0 903.0 903.0
Announcement Date 2/13/20 2/12/21 2/10/22 2/9/23 2/14/24 - - -
1JPY in Million2JPY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 21,518 26,056 31,635 36,264 41,425 49,200 58,000 66,000
EBITDA 1 1,603 2,186 2,879 3,525 - 4,400 5,220 6,440
EBIT 1 1,492 2,068 2,798 3,391 3,665 4,200 5,000 6,200
Operating Margin 6.93% 7.94% 8.84% 9.35% 8.85% 8.54% 8.62% 9.39%
Earnings before Tax (EBT) 1 1,501 2,148 2,818 3,035 3,681 4,230 5,000 6,200
Net income 1 989 1,446 1,905 2,082 2,518 2,850 3,400 4,250
Net margin 4.6% 5.55% 6.02% 5.74% 6.08% 5.79% 5.86% 6.44%
EPS 2 16.33 23.87 31.49 34.45 41.66 47.10 56.20 70.30
Free Cash Flow 716 1,892 - 1,283 1,746 - - -
FCF margin 3.33% 7.26% - 3.54% 4.21% - - -
FCF Conversion (EBITDA) 44.67% 86.56% - 36.4% - - - -
FCF Conversion (Net income) 72.4% 130.84% - 61.62% 69.34% - - -
Dividend per Share 2 4.500 7.000 9.000 11.00 13.00 14.00 17.00 20.00
Announcement Date 2/13/20 2/12/21 2/10/22 2/9/23 2/14/24 - - -
1JPY in Million2JPY
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2019 S2 2020 S1 2020 S2 2021 S1 2021 Q3 2021 Q4 2021 S2 2022 Q1 2022 Q2 2022 S1 2022 Q3 2022 Q4 2022 S2 2023 Q1 2023 Q2 2023 S1 2023 Q3 2024 Q1 2024 Q2 2024 S1 2024 Q3 2024 Q4 2024 S2
Net sales 1 11,178 12,162 13,894 15,218 8,061 8,356 16,417 8,792 8,812 17,604 9,161 9,499 18,660 9,857 9,924 19,781 10,645 11,200 11,500 22,700 12,800 13,700 26,500
EBITDA - - - - - - - - - - - - - - - - - - - - - - -
EBIT 1 717 985 1,083 1,403 756 639 1,395 913 800 1,713 849 829 1,678 992 809 1,801 925 850 850 1,700 1,150 1,350 2,500
Operating Margin 6.41% 8.1% 7.79% 9.22% 9.38% 7.65% 8.5% 10.38% 9.08% 9.73% 9.27% 8.73% 8.99% 10.06% 8.15% 9.1% 8.69% 7.59% 7.39% 7.49% 8.98% 9.85% 9.43%
Earnings before Tax (EBT) 1 - 991 1,157 1,414 761 643 1,404 917 808 1,725 855 455 1,310 997 816 1,813 929 850 870 1,720 1,150 1,360 2,510
Net income 1 468 664 782 956 526 423 949 626 551 1,177 586 319 905 695 558 1,253 635 630 550 1,180 800 870 1,670
Net margin 4.19% 5.46% 5.63% 6.28% 6.53% 5.06% 5.78% 7.12% 6.25% 6.69% 6.4% 3.36% 4.85% 7.05% 5.62% 6.33% 5.97% 5.62% 4.78% 5.2% 6.25% 6.35% 6.3%
EPS - 10.97 - 15.78 8.700 - - 10.36 - 19.48 9.690 - - 11.50 - 20.73 10.51 - - - - - -
Dividend per Share - - - - - - - - - - - - - - - - - - - - - - -
Announcement Date 2/13/20 8/13/20 2/12/21 8/12/21 11/11/21 2/10/22 2/10/22 5/12/22 8/10/22 8/10/22 11/10/22 2/9/23 2/9/23 5/10/23 8/7/23 8/7/23 11/7/23 - - - - - -
1JPY in Million
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt - - - - - - - -
Net Cash position 3,472 4,497 5,632 6,036 5,488 - - -
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 716 1,892 - 1,283 1,746 - - -
ROE (net income / shareholders' equity) 21.4% 25.8% 27.9% 25.3% 25.4% 24.1% 24.3% 25.4%
ROA (Net income/ Total Assets) 17.6% 20.5% 22% 22.7% 21% 20.2% 20.5% 21.8%
Assets 1 5,620 7,043 8,665 9,161 11,993 14,109 16,585 19,495
Book Value Per Share 2 82.90 102.0 124.0 149.0 179.0 212.0 251.0 302.0
Cash Flow per Share 17.50 25.20 32.80 36.60 44.70 - - -
Capex 1 63 84.9 56.6 298 34 200 220 240
Capex / Sales 0.29% 0.33% 0.18% 0.82% 0.08% 0.41% 0.38% 0.36%
Announcement Date 2/13/20 2/12/21 2/10/22 2/9/23 2/14/24 - - -
1JPY in Million2JPY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Elan Corporation

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Healthcare Facilities & Services

1st Jan change Capi.
ELAN CORPORATION Stock Elan Corporation
-19.09% 347M
HCA HEALTHCARE, INC. Stock HCA Healthcare, Inc.
+14.10% 81.84B
CVS HEALTH CORPORATION Stock CVS Health Corporation
-30.15% 70.69B
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY Stock Dr. Sulaiman Al Habib Medical Services Group Company
+9.37% 29.03B
LABORATORY CORPORATION OF AMERICA HOLDINGS Stock Laboratory Corporation of America Holdings
-11.90% 16.97B
FRESENIUS SE & CO. KGAA Stock Fresenius SE & Co. KGaA
-0.36% 16.83B
QUEST DIAGNOSTICS INCORPORATED Stock Quest Diagnostics Incorporated
-1.12% 15.28B
FRESENIUS MEDICAL CARE AG Stock Fresenius Medical Care AG
+5.90% 12.41B
DAVITA INC. Stock DaVita Inc.
+35.78% 12.26B
EUROFINS SCIENTIFIC SE Stock Eurofins Scientific SE
-4.20% 11.86B
Other Healthcare Facilities & Services
  1. Stock Market
  2. Equities
  3. 6099 Stock
  4. Financials Elan Corporation